<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04668781</url>
  </required_header>
  <id_info>
    <org_study_id>3169/2018</org_study_id>
    <nct_id>NCT04668781</nct_id>
  </id_info>
  <brief_title>Improvement of Care of Patients Undergoing Pancreaticoduodenectomy</brief_title>
  <official_title>Improvement of Care of Patients Undergoing Pancreaticoduodenectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Helsinki</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a randomised controlled trial comparing the effectivity and impact of epidural&#xD;
      analgesia and wound catheter analgesia in patients undergoing pancreaticoduodenectomy. The&#xD;
      aim of the study is to examine whether there are a difference in perioperative fluid therapy&#xD;
      and complication rates between the patients in epidural and wound catheter groups.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients undergoing pancreaticoduodenectomy in Helsinki University Hospital are recruited&#xD;
      in the study. Patients meeting the inclusion criteria and giving consent to participate the&#xD;
      study will be randomised to whether epidural analgesia group or wound catheter analgesia&#xD;
      group. Both groups get additional analgesia with intravenous PCA-oxycodone (patient&#xD;
      controlled analgesia).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 21, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fluid volume intraoperatively and postoperatively</measure>
    <time_frame>postoperative day 0-7</time_frame>
    <description>The amount of fluid (crystalloids and albumin) patients have got during the surgery and postoperatively (ml/kg).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The amount of used norepinephrine</measure>
    <time_frame>postoperative day 0-7</time_frame>
    <description>The amount of norepinephrine patients have got intraoperatively and postoperatively (mg/kg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total dose of oxycodone</measure>
    <time_frame>postoperative day 0-7</time_frame>
    <description>The amount of oxycodone patients have dosed via i.v. PCA pump (mg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>postoperative day 0-60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complications</measure>
    <time_frame>postoperative day 0-30</time_frame>
    <description>Clavien-Dindo complications (scale 0-5), pancreatic fistulas (ISGPF definition, grade A-C), postpancreatectomy hemorrage (IPGPS definition, grade A-C), delayed gastric emptying (ISGPS definition, grade A-C).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reoperation rates</measure>
    <time_frame>postoperative day 0-30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmission rates</measure>
    <time_frame>postoperative day 0-30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>postoperative day 0-90</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Pancreatic Diseases</condition>
  <condition>Pancreas Cancer</condition>
  <arm_group>
    <arm_group_label>Epidural analgesia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Wound catheter analgesia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Analgesia via epidural catheter</intervention_name>
    <description>Ropivacain-infusion 2 mg/ml 1,25ml/h/10kg IBW (ideal body weight) is started to patients in the beginning of the surgery and is continued to POD 4. The rest of the treatment obey study protocol in both groups.</description>
    <arm_group_label>Epidural analgesia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Analgesia via wound catheter</intervention_name>
    <description>Ropivacain 5 mg/ml 2,5ml/10kg IBW (ideal body weight) is given to patients in the end of the surgery. After that ropivacain-infusion 2mg/ml 1,25ml/h/10kg IBW is started to patients and is continued to POD 4. The rest of the treatment obey study protocol in both groups.</description>
    <arm_group_label>Wound catheter analgesia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age 18 years or over&#xD;
&#xD;
          -  patients who undergo pancreaticoduodenectomy without vascular recostruction&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients to whom are made a vascular reconstruction&#xD;
&#xD;
          -  patients who have significantly elevated risk for complications&#xD;
&#xD;
          -  regural use of strong opioids or drugs preoperatively&#xD;
&#xD;
          -  patients with severe chronic pain issues&#xD;
&#xD;
          -  chronic atrial fibrillation&#xD;
&#xD;
          -  patients who refuse to take part to the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Piia Peltoniemi, M.D.</last_name>
    <phone>+35894711</phone>
    <email>piia.peltoniemi@hus.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pertti Pere, Ass.Prof</last_name>
    <phone>+35894711</phone>
    <email>pertti.pere@hus.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <state>HUS</state>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piia Peltoniemi, M.D.</last_name>
      <phone>+35894711</phone>
      <email>piia.peltoniemi@helsinki.fi</email>
    </contact>
    <contact_backup>
      <last_name>Pertti Pere, M.D, docent</last_name>
      <phone>+35894711</phone>
      <email>pertti.pere@hus.fi</email>
    </contact_backup>
    <investigator>
      <last_name>Piia Peltoniemi, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pertti Pere, Ass.Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hanna Sepp√§nen, Ass.Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Teija Nieminen, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arto Kokkola, Ass.Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 9, 2020</study_first_submitted>
  <study_first_submitted_qc>December 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2020</study_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Piia Peltoniemi</investigator_full_name>
    <investigator_title>M.D., Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>pancreaticoduodenectomy</keyword>
  <keyword>fluid therapy</keyword>
  <keyword>enhanced recovery after surgery (ERAS)</keyword>
  <keyword>postoperative complications</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Pancreatic Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

